Most Popular
-
1
Contentious grain bill put directly to plenary meeting for vote
-
2
Yoon's approval rating plunges to all-time low
-
3
Climate impacts set to cut 2050 global GDP by nearly a fifth
-
4
Trilateral talks acknowledge ‘serious’ slumps of won, yen
-
5
North Korea removes streetlights along cross-border roads with South
-
6
Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
-
7
S. Korea votes in favor of Palestinian bid for UN membership
-
8
Bae Doo-na shares portraying Korean identity in Hollywood's 'Rebel Moon'
-
9
[From the Scene] Monks, Buddhists hail return of remains of Buddhas
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
-
10
Medical schools granted enrollment quota flexibility for next year
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
[THE INVESTOR] Cha Biotech announced on Aug. 3 that it will collaborate with US-based Sorrento Therapeutics in developing immunotherapy.
The research will be conducted by a joint venture between the two companies.
Cha Biotech will hold 51 percent stake in the company.
Under the agreement, the two companies will collaborate in splicing the gene for chimeric antigen receptor into natural killer cells. Chimeric antigen receptor or CAR are engineered to have specificity to selected proteins.
Natural killer cells that express CAR will detect and attack only the cancer cells expressing the protein specific to CAR.
By Choi He-suk (cheesuk@heraldcorp.com)
The research will be conducted by a joint venture between the two companies.
Cha Biotech will hold 51 percent stake in the company.
Under the agreement, the two companies will collaborate in splicing the gene for chimeric antigen receptor into natural killer cells. Chimeric antigen receptor or CAR are engineered to have specificity to selected proteins.
Natural killer cells that express CAR will detect and attack only the cancer cells expressing the protein specific to CAR.
By Choi He-suk (cheesuk@heraldcorp.com)
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Illit drops debut single remix](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/19/20240419050612_0.jpg&u=)